Avenue Therapeutics completes Phase 1b/2a trial for SBMA and plans Phase 2a trial for epilepsy, pending financing.

Avenue Therapeutics has completed the final patient visit in its Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy (SBMA), or Kennedy's Disease, with topline data expected in H2 2024. The company aims to start a Phase 2a trial of BAER-101 for epilepsy and other seizure disorders, subject to further financing. Avenue Therapeutics also agreed on a safety study protocol and statistical analysis approach for the Phase 3 study of intravenous tramadol for acute post-operative pain, pending additional financing or partnership. The company raised $4.4m in gross proceeds from a warrant exercise transaction in 2024, and cash and cash equivalents totaled $4.9m as of June 30, 2024.

August 09, 2024
3 Articles

Further Reading